Dr. Raid Aljumaily

About Raid Aljumaily

Education:

• Graduated with an MD from the University of Baghdad College of Medicine, Iraq, in 2009.
• Completed a Residency in Internal Medicine at the University of Oklahoma Health Sciences Center in 2016.
• Finished a Fellowship in Hematology/Oncology at the University of Oklahoma Health Sciences Center in 2019.

Experience:

• Has been serving as an Assistant Professor of Medicine at the University of Oklahoma Health Sciences Center since 2019.
• Specializes in hematologic malignancies, lymphoma, and myelodysplastic syndromes.

Area of expertise

Affiliated Hospitals

University Of Oklahoma Health Sciences Center

Cancer Centers Of Southwest Oklahoma Research

Clinical Trials Raid Aljumaily is currently running

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.

Recruiting2 awards Phase 331 criteria

Monalizumab or Oleclumab with Durvalumab and Radiation

for Lung Cancer

This phase I trial studies the safety of adding durvalumab to accelerated hypofractionated radiation therapy (ACRT) or conventionally fractionated radiation therapy, as well as the safety of adding either monalizumab or oleclumab to durvalumab plus conventionally fractionated radiation therapy in treating patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (locally advanced). Accelerated hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Immunotherapy with monoclonal antibodies, such as durvalumab and monalizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Oleclumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD73, which is found on some types of tumor cells. Oleclumab may block CD73 and help the immune system kill tumor cells. It is not yet known whether adding durvalumab to ACRT or adding monalizumab or oleclumab to durvalumab plus conventionally fractionated radiation therapy will work better in treating patients with non-small cell lung cancer.

Recruiting1 award Phase 110 criteria

More about Raid Aljumaily

Other Doctors you might be interested in

Frequently asked questions